The observed detrimental impact of insulin-treated DM on PR under prasugrel may simply reflect platelet dysfunction of unclear clinical significance, considering the excellent performance of this agent in insulin-treated DM in TRITON-TIMI 38- with a 37 % reduction in the primary endpoint compared to clopidogel [10]. Here, INS is linked to diabetes mellitus.